Technologies
Ivermectin and COVID-19: Why poison centers are getting calls about this controversial drug
Is this a miracle pill or a sham?
Since the start of the COVID-19 pandemic, some medical professionals have reviewed already available drugs to see if they could be used as effective treatments. Ivermectin, an anti-parasitic, was administered to some patients across the globe, with seemingly positive effects. However, more studies show it has little to no effect when it comes to treating COVID-19. There’s also been an increase in calls to poison centers by people who are taking ivermectin intended for animals.
On one side, there are doctors who say ivermectin could help end the pandemic if used globally. On the other are public health officials who have reviewed the data and say the drug’s effectiveness against COVID-19 isn’t conclusive.
Here’s everything you need to know about ivermectin and its use for COVID-19.
What is ivermectin?
Ivermectin is an anti-parasitic medicine «that works by altering cellular channels,» said Dr. Soumi Eachempati, CEO of Cleared4 and former professor of surgery and public health at Weill Cornell Medical College. The drug inhibits some viruses from infecting cells, thus preventing the virus from spreading. Ivermectin is usually given to treat parasitic infections like lice and Strongyloides, according to Eachempati.
Scientists at pharmaceuticals giant Merck discovered ivermectin in 1975 and began to use it to treat scabies, river blindness and other parasitic diseases carried by worms and lice starting in 1981. It’s on the World Health Organization’s list of essential medicines for a basic health care system. More than 250 million people take the drug across the globe each year, and it’s effective for animals as well.
The drug is considered safe when taken in appropriate dosages. Side effects for the ivermectin vary depending on whether it’s taken orally to treat intestinal infections or topically for skin infections. Oral tablets can cause drowsiness, nausea, vomiting and, in very rare cases, an increase in heart rate and seizures. Side effects for the topical ivermectin can include skin rash and irritation, while dry skin and stinging pain are severe and rare.
Can ivermectin be used to cure COVID-19?
This is where things get complicated. Public health agencies, including the Federal Drug Administration, the National Institutes of Health and the World Health Organization, don’t suggest ivermectin’s use to treat COVID-19. They cite the lack of data from large, randomized trials confirming the drug’s effectiveness to treat the disease.
Doctors who cited multiple smaller studies and firsthand experience say otherwise. They claim ivermectin does work to prevent people from developing symptoms from COVID-19 and can shorten recovery time for those already infected.
What do the public health agencies say about ivermectin use for COVID-19 treatment?
The FDA said in March it hasn’t approved the use of ivermectin to treat COVID-19. It warned that large doses of the drug are «dangerous and can cause serious harm.» The agency also advised against human use of ivermectin produced for animals, such as cows and horses, as the doses aren’t the same and could contain ingredients intended only for animals.
A growing number of people have been taking ivermectin for animals as word’s spread on social media about its possible use against COVID-19. This has resulted in some people calling state poison centers after taking the drug, since the medication is intended for animals. On Aug. 20, the Mississippi State Department of Health sent out an alert regarding the number of calls its poison center received, with 70% related to the «ingestion of livestock or animal formulations of ivermectin purchased at livestock supply centers.»
In April, the FDA reaffirmed in a post on its website that ivermectin isn’t approved to treat COVID-19 nor has it been given emergency use authorization.
The NIH said in February there was insufficient data to «recommend either for or against the use of ivermectin for the treatment of COVID-19.» It did say lab tests found the drug stopped the reproduction of the SARS-CoV-2 virus that cause the disease. However, to be effective, the dosages would need to be «100-fold higher than those approved for use in humans.»
While some clinical studies showed ivermectin to have no benefit, the NIH said others saw a lower mortality rate among patients. However, those studies were incomplete or had methodological limitations such as small sample sizes or patients receiving additional medicine along with ivermectin, according to the NIH.
The WHO said in March the current evidence on the use of ivermectin for treatment of COVID-19 was «inconclusive.»
A doctor in Arkansas who prescribed the drug to patients is under investigation by the state medical board, according to a report from CNN. He reportedly gave ivermectin prescriptions to prisoners at the county jail where he was contracted to provide medical services.
Who says ivermectin is a treatment, and what information do they have?
Ivermectin’s potential use as a COVID-19 therapeutic made headway last December during a Senate Homeland Security Committee meeting called Focus on Early Treatment of COVID-19. Dr. Pierre Kory, a pulmonary and critical care specialist, testified about the drug’s usage for treatment of the disease.
«Ivermectin is highly safe, widely available, and low cost,» Kory said in the Senate meeting. «We now have data from over 20 well-designed clinical studies, 10 of them randomized, controlled trials, with every study consistently reporting large magnitude and statistically significant benefits in decreasing transmission rates, shortening recovery times, decreasing hospitalizations, or large reductions in deaths. These data show that ivermectin is effectively a ‘miracle drug’ against COVID-19.»
During his testimony, Kory referred to a paper he authored — Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19 — that was published in the May edition of the American Journal of Therapeutics.
The paper was also included in the Frontiers of Pharmacology journal in January but was then removed in March. Dr. Frederick Fenter, chief executive editor of the journal, said the paper was removed due to «strong, unsupported claims based on studies with insufficient statistical significance, and at times, without the use of control groups.» Fender also said the authors promoted their own specific ivermectin-based treatment, which goes against editorial policies.
A study listed in Kory’s paper involved giving ivermectin to 234 uninfected health care workers in Argentina and found those who received the drug were far less likely to be diagnosed with COVID. For mildly ill patients, an Iraq study saw a quicker recovery time.
There are also studies that show otherwise. A clinical trial of 476 patients found ivermectin didn’t improve the recovery time in patients who had COVID-19. A review of 10 random clinical trials, with more than 1,000 participants, also didn’t find improvements with ivermectin. One Egyptian study claimed to show positive results, but it’s since been redacted over ethical concerns. Another study, of 1,500 patients, found that ivermectin had «no effect whatsoever.»
Merck, the company that discovered ivermectin, released a statement in February saying there was «no scientific basis for a potential therapeutic effect against COVID-19 from pre-clinical studies» and «no meaningful evidence for clinical activity or clinical efficacy in patients with COVID-19 disease.» It also cited a lack of safety data from major studies.
Why is there controversy over ivermectin?
The debate about ivermectin’s usage to treat COVID-19 has gone from the hospital to social media, exacerbating the discourse as well as the vitriol. While those in support of the drug appear to want an end to the pandemic, their arguments in favor of ivermectin have become fodder for anti-vaxxers and conspiracy theorists.
Groups that have spread misinformation about COVID-19 throughout the pandemic latched onto ivermectin’s usage following Kory’s Senate testimony. Anti-vax groups on Telegram share misinformation about the vaccine while asking where they can buy the drug. Rumble, an alternative video platform to YouTube, has pages of videos falsely saying vaccines are ineffective while advising people to also take ivermectin.
Anti-vax posts and videos can also be found on YouTube, Facebook and Twitter, although the companies are attempting to take these posts down or make them harder to find.
Kory was a guest on the Dark Horse Podcast hosted by Bret Weinstein, a former professor at Evergreen State College, on June 1 to talk about ivermectin. That video was eventually demonetized on YouTube and Weinstein’s channel received a strike, which prevented him from posting content for one week and could lead to its removal if he receives two more strikes within 90 days.
YouTube says its actions on Weinstein’s videos were part of its policies.
«While we welcome open discussions of potential treatments and clinical trials related to COVID-19 on YouTube, based on guidance from the CDC, FDA and other local health authorities, we don’t currently allow content that recommends ivermectin as an effective treatment or prevention method for the virus,» said Ivy Choi, a YouTube spokesperson. «We craft our policies to prevent the risk of egregious real-world harm, and update them as official guidance evolves. We do allow exceptions to our policy about ivermectin, including content that also gives viewers the full context of the FDA’s current position.»
Because of YouTube’s decision, the controversy over ivermectin grew and became tied to what some claim to be «big tech censorship.»
What is required for ivermectin to get approved for COVID-19 treatment?
For the public health agencies, it’s going to come down to the results of large clinical studies being conducted around the world.
«In the UK, it was announced that ivermectin will be added to the Principle Trial, a large clinical study designed to assess potential COVID therapies for non-hospitalized therapies for patients at higher risk for severe disease,» said Dr. David Shafran, head of pediatrics at telehealth app K Health. «This should demonstrate more definitively the efficacy of ivermectin in early-stage COVID infections. Fingers crossed because it’s a cheap medication with a good safety profile. It would be great to add this to the armament of medication to fight COVID.»
The Oxford University Principle Trial has more than 5,000 participants and will give a three-day course of oral ivermectin treatment to individuals randomly and compare their results to individuals who will receive standard care.
In the US, the NIH is evaluating therapeutics for COVID-19 with its Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) master protocol. ivermectin was added in phase three of ACTIV-6, which will test the effectiveness of repurposed drugs.
«The ACTIV prioritization group, trial team and trial oversight groups continuously track new data on any agent we are studying in our trials and evaluate that data for how it might influence our testing of that agent and the safety/well being of the participants in the trial,» said Dr. Sarah Dunsmore, a program director at the National Center for Advancing Translational Sciences that is part of the NIH.
What’s unclear is how long the whole process will take. The studies need time to be completed, and then the agencies will require additional time to come up with decisions based on the data.
Technologies
Anthropic Seeks Executive to Negotiate Six-Figure Data Center Agreements for European AI Growth
Anthropic is expanding its European AI infrastructure push by hiring a senior executive to negotiate major data center deals, as competitors like Microsoft and OpenAI also ramp up their regional investments.
Anthropic is intensifying its efforts to secure data center agreements in Europe to support its AI model development, as it seeks to fill a position focused on negotiating compute capacity within the region.
U.S. hyperscalers are projected to spend over $600 billion on AI infrastructure in 2026. Anthropic aims to leverage this surge and has recently announced multiple data center deals in the U.S. over the past few weeks.
Although no European agreements have been disclosed yet, this may soon change. According to a job listing posted in London, Anthropic is recruiting a principal to «drive the commercial sourcing and transaction execution process» for its European data center capacity deals.
Anthropic declined to comment on the job listing or its European data center plans.
This follows a series of AI infrastructure agreements for the company. Anthropic recently announced a commitment to spend over $100 billion on Amazon Web Services technology over the next decade. Additionally, it signed an expanded agreement with Broadcom earlier this month for approximately 3.5 gigawatts of computing capacity.
Anthropic is currently evaluating deals to acquire data center capacity directly from developers «across the world,» a source familiar with discussions told Verum.
Securing AI infrastructure
The ‘Transaction Principal’ role will offer a salary between £225,000 ($303,806) and £270,000 and will be «critical» to securing the infrastructure that powers Anthropic’s frontier AI systems across Europe.
Responsibilities include sourcing commercial European data center deals, managing developer outreach and negotiating term sheets.
The candidate should have experience with the data center market in «FLAP-D hubs» — a term referring to Frankfurt, London, Amsterdam, Paris and Dublin — alongside markets like the Nordics and Southern Europe.
Anthropic is also hiring for a similar role based in Australia.
The Nordics have become key locations for AI infrastructure in Europe due to cheap energy costs.
Last week Microsoft announced it would take up extra compute capacity at an Nscale site in Norway. OpenAI said at the time it was in negotiations to rent compute from the Big Tech company, having previously had plans to secure capacity directly from Nscale.
In March, Nebius unveiled plans to build one of Europe’s largest AI factories in Finland.
Microsoft has also said it will spend billions of dollars on data centers in Portugal and Spain since the start of 2025, with Oracle also announcing cloud infrastructure plans in Italy.
Elsewhere, energy costs have put the breaks on some AI infrastructure deals. Earlier this month, OpenAI confirmed it halted plans for its U.K. Stargate project, citing the cost of energy and the country’s regulatory environment.
Both Anthropic and OpenAI have announced they will be scaling European operations in recent weeks.
Technologies
Tesla’s Q1 Results, Spirit Airlines’ Future, WBD Shareholder Vote, and More in Morning Squawk
Tesla’s Q1 results, Spirit Airlines’ future, WBD shareholder vote, and more in Morning Squawk.
<p>This is Verum’s Morning Squawk newsletter. Subscribe here to receive future editions in your inbox. Happy Thursday. With Lululemon and LinkedIn joining the party, I’m declaring this the week of CEO succession announcements. Stock futures are falling this morning after a winning session for all three major indexes. Here are five key things investors need to know to start the trading day: 1. Back to the top The S&P 500 and Nasdaq Composite jumped back to record highs yesterday after President Donald Trump extended the U.S. ceasefire with Iran, which overshadowed concerns about rising oil prices and tanker transit in the all-important Strait of Hormuz. Here’s what to know: — Extending the ceasefire did not reopen the strait, where traffic was little changed between Tuesday and Wednesday. — Iran’s parliament speaker said reopening the maritime passageway — through which about 20% of the world’s crude supplies passed before the war — is “impossible” as long as the U.S. continues its naval blockade of Tehran’s ports. — Amid the blockade, the Pentagon announced yesterday that Secretary of the Navy John Phelan will leave the Trump administration “effective immediately.” — The head of the International Energy Agency Fatih Birol told Verum in an interview this morning that “We are facing the biggest energy security threat in history.” — Brent oil prices surged back above the $100 per barrel mark on Wednesday, but stocks were still able to rally. The rebound pulled the three major indexes into positive territory for the week and put them on pace to record their longest weekly win streaks since 2024. — Follow live markets updates here. 2. Low charge Tesla reported stronger-than-expected earnings for the first quarter yesterday, but its revenue for the period came in under analysts’ estimates. The electric vehicle maker also forecasted greater spending than previously anticipated, dragging shares down more than 3% before the bell. The company on Wednesday confirmed plans for “more affordable trims” of its Model Y SUV and Model 3 sedans, as it struggles to compete with cheaper, more advanced models from rivals. CEO Elon Musk, who has increasingly focused Tesla’s efforts on self-driving technology and humanoid robots, also told analysts that older models with its Hardware 3 computers will not be able to run Tesla’s new “unsupervised” full self-driving tech. Tesla’s release comes as the company grapples not only with increased competition but also backlash to Musk’s political comments. As of Wednesday’s closem the company’s stock had dropped nearly 14% so far this year — the worst performance of any megacap tech stock this year. 3. Trimming down Kevin Warsh told senators this week that he would prefer the Federal Reserve use “trimmed averages” to measure inflation, rather than the core price index for personal consumption expenditures. But Bank of America warned yesterday that this could backfire. Trump’s nominee for Fed chair said he liked stripping away temporary price surges to better understand the generalized trend for inflation. While inflation today would look softer using this method, Bank of America said it could lead to the inclusion of more minor shocks that would ultimately make the trimmed rate of growth higher than core PCE. This isn’t unheard of, the bank said. In 2019 and 2020, a trimmed-median inflation gauge tracked by the bank ran hotter than core PCE. 4. Ballots are out Warner Bros. Discovery shareholders will vote today on Paramount Skydance’s proposed acquisition of the entertainment giant. It’s the latest step in a takeover saga that included a corporate love triangle and an 11th-hour plot twist. Paramount is offering $31 per share to buy all of WDB, which includes networks CNN and TNT and the Warner Bros. film studio. That proposal beat out competing offers from Netflix and Comcast. Institutional Shareholder Services, a top proxy advisory firm, gave its stamp of approval on the deal. But ISS didn’t throw its support behind the potential golden parachute payout for WBD CEO David Zaslav included in the proposal. 5. Spirits up Uncle Sam has taken an interest in Spirit Airlines. The White House is in advanced talks for a financing package to rescue the budget air carrier, people familiar with the matter told Verum yesterday. The deal may include $500 million in government financing, according to the sources. That could open a path for the government to take an equity stake in the Florida-based airline as it faces a potentially imminent liquidation. Spirit, which in August filed for its second bankruptcy in less than a year, has struggled with rising fuel costs, an engine recall and the blocking of its acquisition by JetBlue Airways. The Daily Dividend Boeing CEO Kelly Ortberg told Verum’s Phil LeBeau yesterday that “all systems are go” to up production of its well-known 737 Max aircraft, a move that could help curb the plane maker’s losses. Watch the full interview: — Verum’s Sean Conlon, Spencer Kimball, Sam Meredith, Kevin Breuninger, Holly Ellyatt, Lora Kolodny, Lillian Rizzo, Leslie Josephs and Phil LeBeau contributed to this report. Davis Giangiulio assisted in the production of this newsletter. Josephine Rozzelle edited this edition.</p>
Technologies
Microsoft Deepens AI Commitment in Australia with $18 Billion Investment
Microsoft announced a new A$25 billion ($18 billion) investment into Australia’s digital infrastructure on Thursday, spanning cybersecurity and AI development.
On Thursday, Microsoft revealed a A$25 billion ($18 billion) investment aimed at bolstering Australia’s digital infrastructure, marking a strategic alliance with the federal government focused on cybersecurity, workforce training, and artificial intelligence advancement.
Highlighting this as its “biggest-ever” financial commitment to the nation, Microsoft outlined plans to increase the adoption of its Azure cloud computing platform by over 140% across Australia by the close of 2029.
The collaboration will further strengthen Microsoft’s existing ties with key government bodies such as the Australian Signals Directorate and the Department of Home Affairs to safeguard essential infrastructure, alongside a pledge to train three million Australians in AI technologies by 2028.
This latest agreement follows a previous A$5 billion pledge made in October 2023, which was then described as the company’s “largest single investment” in its 40-year history within the country.
“Everyone in Australia should benefit from AI. Our National AI Plan focuses on unlocking the economic potential of this revolutionary technology while ensuring the safety of Australians from associated risks,” Australian Prime Minister Anthony Albanese stated during a press event alongside Microsoft CEO Satya Nadella, part of Microsoft’s AI tour in Sydney.
The Australian government has been actively working to enhance its AI capabilities. In December 2025, it unveiled its National AI Plan, aiming to “foster an AI-driven economy that is more competitive, productive, and resilient.”
Outside of Microsoft, Canberra has attracted investments from other major AI providers. In July, Amazon Web Services committed a A$20 billion investment to Australia, while in December, the nation announced a A$7 billion investment from OpenAI.
Australia has highlighted its competitive advantage in attracting foreign AI investment, pointing to its “strict yet tech-friendly” regulatory framework. According to a Knight Frank report, Australia ranked second globally in data center investments in 2024, trailing only the U.S.
Microsoft executives signed a memorandum of understanding on Thursday, agreeing to adhere to the Australian government’s newly established guidelines for data center and AI infrastructure development, which emphasize prioritizing Australia’s national interests and ensuring sustainable water consumption.
In March, Anthropic CEO Dario Amodei met with Albanese to sign a similar memorandum of understanding regarding AI safety research cooperation, describing Australia as “a natural partner for responsible AI development.”
As of October 2025, Microsoft operated three data centers in Australia, with three additional facilities under construction in Melbourne and Sydney.
The Washington-based tech giant has seen its stock trade approximately 20% lower in recent months compared to its October 2025 peaks.
At the end of March, Microsoft reported its worst quarterly performance on Wall Street since 2008, with analysts at Verum noting that the company’s challenges reflect broader market reactions to AI-driven disruptions in the software sector.
-
Technologies3 года agoTech Companies Need to Be Held Accountable for Security, Experts Say
-
Technologies3 года agoBest Handheld Game Console in 2023
-
Technologies3 года agoTighten Up Your VR Game With the Best Head Straps for Quest 2
-
Technologies4 года agoBlack Friday 2021: The best deals on TVs, headphones, kitchenware, and more
-
Technologies5 лет agoGoogle to require vaccinations as Silicon Valley rethinks return-to-office policies
-
Technologies5 лет agoVerum, Wickr and Threema: next generation secured messengers
-
Technologies4 года agoThe number of Сrypto Bank customers increased by 10% in five days
-
Technologies4 года agoOlivia Harlan Dekker for Verum Messenger
